Axsome Therapeutics has begun the Phase 3 CLARITY trial of solriamfetol in adults with major depressive disorder and excessive daytime sleepiness. The study focuses on a patient group that currently ...

Patients with major depressive disorder and patients with inflammatory skin diseases like atopic dermatitis share similar immune abnormalities, notably in the Th2 pathway, according to a study ...

This study suggests is that clinicians "may be able to offer patients a path to meaningful relief in less than 1 week." ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been ...

A new study suggests wrist-worn sleep trackers may help predict depression relapse weeks early—explore what this means for ...

Major depressive disorder is linked to Th2 immune dysregulation similar to atopic dermatitis. Could dupilumab offer a new ...

No statistically significant change in MADRS total score was observed with solriamfetol vs placebo in the overall study population. Topline results were announced from a phase 3 trial evaluating ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Wearable trackers could even detect the probability of a relapse weeks or months before it occurs. Up to around 60% of people with MDD will experience at least one relapse episode in their lifetime.

The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...

High placebo responses common in tests of neuropsychiatric drugs make any clinical trial in major depressive disorder risky. Intra-Cellular Therapies now has data showing its drug met key goals of a ...